BRAF mutant gastrointestinal stromal tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance

G. S. Falchook, J. C. Trent, M. C. Heinrich, C. Beadling, J. Patterson, C. C. Bastida, S. C. Blackman, R. Kurzrock

Research output: Contribution to journalArticlepeer-review

89 Scopus citations

Fingerprint Dive into the research topics of 'BRAF mutant gastrointestinal stromal tumor: First report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance'. Together they form a unique fingerprint.

Medicine & Life Sciences